Effects of Vitamin D deficiency treatment on metabolic markers in Hashimoto thyroiditis patients

Background: the aim of the current trial was to investigate the effect of vitamin d treatment on metabolic markers in people with vitamin d deficiency and thyroid autoimmunity. materials and methods: in this double-blind,randomized,placebo-controlled clinical trial,65 vitamin d deficient euthyroid or hypothyroid patients with positive tpo-ab were enrolled. they randomly allocated into two groups to receive oral vitamin d3 (50000 iu weekly) and placebo for 12 weeks. serum concentration of calcium,phosphorus,albumin,c-reactive protein,blood urea nitrogen,creatinine,glycated hemoglobin (hba1c),insulin,fasting plasma glucose (fpg),triglyceride (tg),total cholesterol,and high-density lipoprotein were measured in both groups before and after the trial. homeostasis model assessment estimates of beta cell function (homa-b) and homa-insulin resistance (homa-ir) were calculated before and after trial in both groups. results: thirty-three and thirty-two participants were allocated to vitamin d-treated and placebo-treated groups,respectively. mean (standard error) level of vitamin d increased significantly in vitamin d-treated group (45.53 [1.84] ng/ml vs. 12.76 [0.74] ng/ml,p = 0.001). the mean of hba1c and insulin was increased significantly both in vitamin d-treated and placebo-treated groups (p < 0.05). other variables did not meet a significant change after trial (p = ns). in between-group comparison,there was not any significant difference between vitamin d-treated and placebo-treated groups regarding measures of homa-b,homa-ir,fpg,hba1c,and tg (p = ns). conclusion: our findings showed that weekly 50000 iu oral vitamin d3 for 12 weeks did not improve metabolic markers,ir,or insulin secretion in vitamin d deficient patients with hashimoto thyroiditis. � 2016 journal of research in medical sciences.